Narula Neeraj, Fedorak Richard N
Division of Gastroenterology, Zeidler Ledcor Centre, University of Alberta, Edmonton, Canada.
Can J Gastroenterol. 2009 Feb;23(2):121-5. doi: 10.1155/2009/431349.
Crohn's disease (CD) is an idiopathic inflammatory bowel disease and has no known cure. CD symptoms are treated using an array of medicines, including biological agents such as infliximab. However, infliximab therapy is expensive; therefore, identifying variables that can help predict response to infliximab is worthwhile. The present article reviews the impact of tobacco smoking on the efficacy of infliximab in CD. Earlier studies have speculated that smoking has a negative effect on the response to infliximab in CD, but the current literature is largely unable to identify a significant relationship between the two. Although smoking is known to have a negative effect on the course of CD, as well as other organ systems, presently, a CD patient's smoking status should not influence treatment decisions regarding infliximab therapy.
克罗恩病（CD）是一种特发性炎症性肠病，目前尚无治愈方法。CD的症状通过一系列药物进行治疗，包括英夫利昔单抗等生物制剂。然而，英夫利昔单抗治疗费用昂贵；因此，确定有助于预测对英夫利昔单抗反应的变量是有价值的。本文综述了吸烟对英夫利昔单抗治疗CD疗效的影响。早期研究推测吸烟对CD患者使用英夫利昔单抗的反应有负面影响，但目前的文献大多无法确定两者之间的显著关系。尽管已知吸烟会对CD病程以及其他器官系统产生负面影响，但目前，CD患者的吸烟状况不应影响关于英夫利昔单抗治疗的决策。
